Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial
Xingzhe Liu, Dan Liu, Zikun Peng, Jianqing Zhu, Weidong Zhao, Yi Huang, Ruifang An, Hong Zheng, Pengpeng Qu, Li Wang, Qi Zhou, Danbo Wang, Ge Lou, Jing Wang, John Low, Beihua Kong, Rutie Yin, Xing Xie, Jihong Liu, Wei Sun, Rongyu Zang, Ding Ma, Qinglei Gao · 2026
Read Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial by Xingzhe Liu, Dan Liu, Zikun Peng, Jianqing Zhu, Weidong Zhao, Yi Huang, Ruifang An, Hong Zheng, Pengpeng Qu, Li Wang, Qi Zhou, Danbo Wang, Ge Lou, Jing Wang, John Low, Beihua Kong, Rutie Yin, Xing Xie, Jihong Liu, Wei Sun, Rongyu Zang, Ding Ma, Qinglei Gao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13386713.txt.
Description
Xingzhe Liu's team reports final survival and long-term safety of olaparib maintenance in relapsed ovarian cancer, in a 2026 phase IIIb analysis. PARP inhibitor maintenance in platinum-sensitive relapsed ovarian cancer lacked long-term Asian data. The L-MOCA study enrolled Asian patients with high-grade epithelial disease across China and Malaysia, giving oral olaparib 300 milligrams twice daily.
After a median follow-up of 73.4 months, median overall survival reached 51.0 months. Survival reached 64.4 months in BRCA-mutated patients versus 40.9 months in BRCA wild-type, and 54.4 months in HRD-positive versus 34.8 months in HRD-negative patients. No new safety signals emerged, and MDS/AML occurred in 1.3 percent of patients.
Catalog record
| CREATOR | Xingzhe Liu, Dan Liu, Zikun Peng, Jianqing Zhu, Weidong Zhao, Yi Huang, Ruifang An, Hong Zheng, Pengpeng Qu, Li Wang, Qi Zhou, Danbo Wang, Ge Lou, Jing Wang, John Low, Beihua Kong, Rutie Yin, Xing Xie, Jihong Liu, Wei Sun, Rongyu Zang, Ding Ma, Qinglei Gao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |